{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:06:39Z","timestamp":1790805999238,"version":"4.1.0"},"reference-count":14,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T00:00:00Z","timestamp":1532995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHD"],"published-print":{"date-parts":[[2018,7,31]]},"DOI":"10.3233\/jhd-189003","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T12:15:26Z","timestamp":1527855326000},"page":"279-286","source":"Crossref","is-referenced-by-count":29,"title":["Huntington\u2019s Disease Clinical Trials Corner: August 2018"],"prefix":"10.1177","volume":"7","author":[{"given":"Filipe B.","family":"Rodrigues","sequence":"first","affiliation":[{"name":"Huntington\u2019s Disease Centre, University College London, UK"},{"name":"Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Portugal"},{"name":"Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Wild","sequence":"additional","affiliation":[{"name":"Huntington\u2019s Disease Centre, University College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JHD-189003_ref1","unstructured":"Vaccinex Inc. Huntington Study Group. VX15\/2503 Treatment for Huntington's Disease, 2015. https:\/\/ClinicalTrials.gov\/show\/NCT02481674"},{"issue":"6","key":"10.3233\/JHD-189003_ref2","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1212\/WNL.0000000000004209","article-title":"The CREST-E study of creatine for Huntington disease: A randomized controlled trial","volume":"89","author":"Hersch","year":"2017","journal-title":"Neurology"},{"key":"10.3233\/JHD-189003_ref3","unstructured":"Massachusetts General Hospital. Creatine Safety. Tolerabil-ity, & Efficacy in Huntington's Disease (CREST-E), 2008. https:\/\/ClinicalTrials.gov\/show\/NCT00712426"},{"issue":"3","key":"10.3233\/JHD-189003_ref4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3233\/JHD-170262","article-title":"Clinical Trials Corner: September 2017","volume":"6","author":"Rodrigues","year":"2017","journal-title":"J Huntingtons Dis"},{"issue":"4","key":"10.3233\/JHD-189003_ref5","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1158\/1535-7163.MCT-14-0924","article-title":"Nonclinical Safety Evaluation of VX15\/a Humanized IgG4 Anti-SEMA4D Antibody","volume":"14","author":"Leonard","year":"2015","journal-title":"Molecular cancer therapeutics"},{"key":"10.3233\/JHD-189003_ref6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.nbd.2015.01.002","article-title":"Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease","volume":"76","author":"Southwell","year":"2015","journal-title":"Neurobiology of Disease"},{"issue":"4","key":"10.3233\/JHD-189003_ref7","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/1078-0432.CCR-15-0431","article-title":"Safety, pharmacokinetics, and pharmacodynamics of a humanized anti-semaphorin 4D antibody, in a first-in-human study of patients with advanced solid tumors","volume":"22","author":"Patnaik","year":"2016","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"4","key":"10.3233\/JHD-189003_ref8","doi-asserted-by":"crossref","first-page":"e367","DOI":"10.1212\/NXI.0000000000000367","article-title":"Safety\/tolerability of the anti-semaphorin 4D Antibody VX15\/in a randomized phase 1 trial","volume":"4","author":"LaGanke","year":"2017","journal-title":"Neurology\u00ae Neuroimmunology & Neuroinflammation"},{"issue":"10","key":"10.3233\/JHD-189003_ref9","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1212\/WNL.0000000000000187","article-title":"PRECREST: A phase II prevention and biomarker trial of creatine in at-risk Huntington disease","volume":"82","author":"Rosas","year":"2014","journal-title":"Neurology"},{"issue":"1","key":"10.3233\/JHD-189003_ref10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00001756-200201210-00029","article-title":"MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment","volume":"13","author":"Puri","year":"2002","journal-title":"NeuroReport"},{"issue":"5","key":"10.3233\/JHD-189003_ref11","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1177\/147323000803600505","article-title":"Reduction in cerebral atrophy associated with ethyl-eicosapentaenoic acid treatment in patients with Huntington\u2019s disease","volume":"36","author":"Puri","year":"2008","journal-title":"The Journal of International Medical Research"},{"key":"10.3233\/JHD-189003_ref12","unstructured":"Massachusetts General Hospital Creatine Safety and Tolerability in Premanifest HD: PRECREST 2008. https:\/\/ClinicalTrials.gov\/show\/NCT00592995 ."},{"issue":"2","key":"10.3233\/JHD-189003_ref13","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/01.wnl.0000194318.74946.b6","article-title":"Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2\u2019dG","volume":"66","author":"Hersch","year":"2006","journal-title":"Neurology"},{"key":"10.3233\/JHD-189003_ref15","doi-asserted-by":"crossref","unstructured":"Rodrigues FB , Wild EJ Huntingtons Disease Clinical Trials Corner: February Journal of Huntington\u2019s Disease 2018;7(1):89\u201398.","DOI":"10.3233\/JHD-189001"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JHD-189003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:50:35Z","timestamp":1777452635000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JHD-189003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,31]]},"references-count":14,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jhd-189003","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,31]]}}}